MannKind to Present at Jefferies Global Healthcare Conference
Rhea-AI Summary
MannKind (Nasdaq: MNKD) announced that CEO Michael Castagna will join a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET.
Live and recorded audio webcasts will be accessible for about 90 days on MannKind’s investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – MNKD
In the May 28 session, MNKD gained 2.54%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Q1 2026 earnings | Positive | -0.3% | Reported higher Q1 2026 revenue and cash with regulatory milestones ahead. |
| May 06 | Pipeline partnership | Positive | +24.5% | Expanded ralinepag DPI program with United Therapeutics and milestone potential. |
| Apr 29 | Earnings date notice | Neutral | +2.9% | Announced timing and webcast details for upcoming Q1 2026 earnings call. |
| Mar 09 | Afrezza data update | Positive | +2.7% | Presented new Afrezza pediatric and adult data and highlighted May 29 PDUFA. |
| Mar 05 | Debt settlement | Positive | -7.8% | Settled remaining 2.50% convertible notes using cash and share issuance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions have been mixed: positive partnership and clinical updates often aligned with gains, while earnings and capital-structure items at times saw negative divergence.
Over the last six months, MannKind has reported growing revenues and multiple pipeline and partnership milestones. On Mar 5, 2026, it settled $36.3M of convertible notes, followed by Afrezza data and a pediatric PDUFA date update on Mar 9. An April earnings-date notice preceded strong Q1 2026 results on May 6, alongside advancing MNKD-201 and a ralinepag DPI collaboration with potential $35M in milestones. The current Jefferies conference appearance fits into this pattern of active investor and scientific outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET.
Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.
About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.
Contacts: Investor Relations Kate Miranda ir@mnkd.com Media Relations Christie Iacangelo media@mnkd.com